Aloxi

Type: Product
Name: Aloxi
First reported Aug 03 2014 - Updated Aug 03 2014 - 1 reports

Eisai (ESALY) Q1 2015 Results - Earnings Call Transcript

Eisai Co Ltd ( OTCPK:ESALY ) Q1 2015 Earnings Conference Call August 1, 2014 3:30 AM ETOperatorThank you for waiting. The time has come. We would like to begin presentation of financial results for the First Quarter Fiscal 2014 by Eisai. Thank you very ... [Publicerad Seeking Alpha - Aug 03 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Buy Dr Reddys Labs; target of Rs 3150: Religare Capital

Religare Capital`s research report on Dr Reddys LaboratoriesSales growth led by US/India: Continued traction in US sales (+51% YoY) and robust domestic growth (+14%) drove the topline. Russia/RoW growth rebounded (+19%) due to a spurt in Russian OTC sales ... [Publicerad Moneycontrol.com - Aug 01 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Court Report -- Part II - July 2014 #2

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases .Acorda Therapeutics Inc. v. Actavis Laboratories FL Inc.1:14-cv-00882; filed July 7, 2014 in the District Court of DelawareInfringement of U.S. Patent Nos. ... [Publicerad JD Supra - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

"Compositions and Methods for Treating Centrally Mediated Nausea and Vomiting" in Patent Application Approval Process

By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors TRENTO, Fabio (Pare, IT); CANTOREGGI, Sergio (Cagiallo, CH); ROSSI, Giorgia (Cernobbio, IT); CANNELLA, Roberta (Varese, IT); BONADEO, Daniele (Casalzuigno, IT), ... [Publicerad Pharmacy Choice - Jul 30 2014]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

Pharmacists Play Key Role in Oncology Revenue Stream

New Orleans—In April 2012, the University of Southern California (USC) Norris Comprehensive Cancer Center in Pasadena opened a hospital-based, outpatient oncology infusion center, where clinical pharmacists have been key in developing cost-savings and ... [Publicerad Pharmacy Practice News - Jul 26 2014]
First reported Jun 22 2014 - Updated Jun 22 2014 - 1 reports

ALOXI (Palonosetron Hydrochloride) Injection [Eisai Inc.]

First reported May 30 2014 - Updated May 30 2014 - 2 reports

FDA approves Eisai's antiemetic agent ALOXI to treat children

The US Food and Drug Administration (FDA) has approved Japanese pharmaceutical firm Eisai's antiemetic agent ALOXI (palonosetron HCI) as an additional indication regarding the prevention of acute nausea and vomiting associated with initial and repeat ... [Publicerad BioPortfolio - May 30 2014]
First reported May 28 2014 - Updated May 29 2014 - 3 reports

ALOXI injection receives FDA approval for prevention of nausea vomiting associated with cancer chemotherapy

Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemoth ... [Publicerad BioPortfolio - May 29 2014]
First reported May 14 2014 - Updated May 15 2014 - 1 reports

Human medicines European public assessment report (EPAR): Aloxi, palonosetron, Revision: 18, Authorised

Entities: Aloxi, Humanism

Quotes

"DRRD’s Q1 PAT at Rs 5.5bn met expectations, as Rs 475mn of fx gains offset the impact of below-expected margins (17.9% vs RCMLe 18.5%). Sales at Rs 35.2bn (+24% YoY) came in line on robust US (+51%) and improving India/Russia sales. Operating profits however at Rs 6.3bn (+66%) were 6% below expectations on higher overheads. We raise our TP to Rs 3,150 as we roll over to Sep’16E EPS. We like DRRD due to improving visibility on key US launches (Copaxone, Aloxi) and discounted valuations (vs. large peers),” says Religare Capital research report."
Infringement of U S Patent Nos. 8,017,615 ( "Low Hygroscopic Aripiprazole Drug Substance and Process for the Preparation Thereof" issued September 13, 2011), 8,580,796 (same title, issued November 12, 2013), and 8,642,760 (same title, issued February 4, 2014) following a Paragraph...
"The dosage forms are extremely versatile and stable owing to their unique design and formulation. This versatility and stability is accomplished by formulating the NK1 antagonist and palonosetron in separate dosage forms and combining the dosage forms in one capsule. Thus, for example, the palonosetron can be formulated in a small gel-cap at a dose of around 0.5 mg, and the netupitant or other NK1 antagonist formulated in a tablet at a dose of about 100 to 150 mg. A capsule can then be filled with one or more palonosetron gel-caps and one or more netupitant (or other NK1 antagonist) tablets, depending on the therapeutic objective for the product. Because the palonosetron and NK1 antagonist are in separate dosage units, they can be formulated without regard to the stability of the other, and without degradation to by-products, for instance (3S)-3-[(3aS)-1-oxo-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinoline-2-yl]-"

More Content

All (13) | News (9) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Eisai (ESALY) Q1 2015 Results - Earnings Call T... [Publicerad Seeking Alpha - Aug 03 2014]
Buy Dr Reddys Labs; target of Rs 3150: Religare... [Publicerad Moneycontrol.com - Aug 01 2014]
Court Report -- Part II - July 2014 #2 [Publicerad JD Supra - Jul 30 2014]
"Compositions and Methods for Treating Centrall... [Publicerad Pharmacy Choice - Jul 30 2014]
Pharmacists Play Key Role in Oncology Revenue S... [Publicerad Pharmacy Practice News - Jul 26 2014]
ALOXI (Palonosetron Hydrochloride) Injection [E... [Publicerad DailyMed Drug Label Updates for the last seven ... - Jun 22 2014]
FDA approves Eisai's antiemetic agent ALOXI to ... [Publicerad BioPortfolio - May 30 2014]
FDA approves Eisai's antiemetic agent ALOXI to ... [Publicerad PBR - News - May 30 2014]
ALOXI injection receives FDA approval for preve... [Publicerad BioPortfolio - May 29 2014]
FDA Approves ALOXI to Prevent Chemotherapy Indu... [Publicerad BioPortfolio - May 29 2014]
FDA Approves ALOXI® (palonosetron HCl) to Preve... [Publicerad PR Newswire: Health - May 28 2014]
Human medicines European public assessment repo... [Publicerad Pending EC decisions and European Public Assess ... - May 14 2014]
Helsinn, Mundipharma ink distribution and licen... [Publicerad PharmaBiz - Dec 23 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ALOXI (Palonosetron Hydrochloride) Injection [E... [Publicerad DailyMed Drug Label Updates for the last seven ... - Jun 22 2014]
Updated Date: Jun 19, 2014 EST ...
FDA approves Eisai's antiemetic agent ALOXI to ... [Publicerad PBR - News - May 30 2014]
The US Food and Drug Administration (FDA) has approved Japanese pharmaceutical firm Eisai's antiemetic agent ALOXI (palonosetron HCI) as an additional indication regarding the prevention of acute nausea and vomiting associated with initial and repeat ...
FDA Approves ALOXI® (palonosetron HCl) to Preve... [Publicerad PR Newswire: Health - May 28 2014]
WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, May 28, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI® (palonosetron HCl) injection for the prevention of acute nausea and vomiting ...
Human medicines European public assessment repo... [Publicerad Pending EC decisions and European Public Assess ... - May 14 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.